Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort

European Journal of Clinical Pharmacology

Volumn 65, Issue 6, 2009, Pages 579-584

  Zhao, Ying ^a,b   Zhai, Desheng ^b,c   He, Hui ^a   Li, Tingting ^a   Chen, Xijing ^a   Ji, Hui ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CACNA1C; Cytochrome P450 3A5; Nimodipine; Pharmacogenomics; Single nucleotide polymorphism

Indexed keywords

ABCB1 PROTEIN, HUMAN; CACNA1C PROTEIN, HUMAN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; GLYCOPROTEIN P; NIMODIPINE; PRIMER DNA;

ALLELE; ARTICLE; CHINA; COHORT ANALYSIS; GENETICS; HUMAN; NUCLEOTIDE SEQUENCE; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADMINISTRATION, ORAL; ALLELES; BASE SEQUENCE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CHINA; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DNA PRIMERS; HUMANS; NIMODIPINE; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 68849093429     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-009-0619-6     Document Type: Article

References (25)

1. Langley M, Sorkin E (1989) Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs 37:669-699 (Pubitemid 19138616)
2. Keyrouz SG, Diringer MN (2007) Clinical review: prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care 11(4):220
3. Sobrado M, López MG, Carceller F, García AG, Roda JM (2003) Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia. Neuroscience 118(1):107-113 (Pubitemid 36369535)
4. López-Arrieta JM, Birks J (2002) Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev (3):CD000147
5. Liu XQ, Ren YL, Qian ZY, Wang GJ (2000) Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol Sin 21(8):690-694
6. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383-391 (Pubitemid 32268418)
7. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T et al (2002) Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71(4):297-303 (Pubitemid 34311459)
8. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K (2002) Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci 70(13):1491-500 (Pubitemid 34164543)
9. Zhang L, Liu XD, Xie L, Wang GJ (2003) P-glycoprotein restricted transport of nimodipine across blood-brain barrier. Acta Pharmacol Sin 24(9):903-906
10. Höcht C, Lazarowski A, Gonzalez NN, Auzmendi J, Opezzo JA, Bramuglia GF et al (2007) Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. Neurosci Lett 413(2):168-172 (Pubitemid 46177404)
11. Arnett DK, Claas SA, Glasser SP (2006) Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol 44(2):107-118 (Pubitemid 43082210)
12. Bremer T, Man A, Kask K, Diamond C (2006) CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics 7(3):271-279
13. Song P, Li S, Meibohm B, Gaber AO, Honaker MR, Kotb M et al (2002) Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS PharmSci 4(4):E29
14. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M et al (2003) The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 43(6):555-564 (Pubitemid 36613114)
15. Zhao Y, Chen X, Yu Q, He H, Sun Y, Gao Z et al (2009) Determination of nimodipine in human plasma by high-performance liquid chromatography- electrospray ionization mass spectrometry and its application to a bioequivalence study. J Chromatogr Sci (In press)
16. Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ et al (2006) Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Can Med Assoc J 174(12):1715-1722
17. Fukuda T, Onishi S, Fukuen S, Ikenaga Y, Ohno M, Hoshino K et al (2004) CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 4 (1):34-39 (Pubitemid 38256603)
18. Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K et al (2007) Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 82(4):410-426 (Pubitemid 47414348)
19. Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R et al (2007) Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 82(5):579-585 (Pubitemid 47622525)
20. Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH et al (2006) Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 80(6):646-656 (Pubitemid 44920220)
21. Deshaies EM, Boulos AS, Drazin D, Popp AJ (2008) Evidence-based pharmacotherapy for cerebral vasospasm. Neurol Res. (Epub)
22. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F (2008) Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens 30(8):744-766
23. Tartara A, Galimberti CA, Manni R, Parietti L, Zucca C, Baasch H et al (1991) Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol 32(3):335-40
24. Liu XD, Zhang L, Xie L (2003) Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats. Eur J Drug Metab Pharmacokinet 28(4):309-313 (Pubitemid 38076277)
25. Kim KA, Park PW, Park JY (2007) Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol 63(1):53-58